Global segment ranking · Healthtech › Biotech

The world’s most valuable gene & cell therapy startups

Therapeutics developers whose main activity is gene therapy, gene and epigenome editing, CAR-T and other cell therapies, including in vivo approaches. Ranked worldwide by AI-estimated valuation. The market sets the value; our AI estimates it.

Edition 0 (beta) · Published September 29, 2026 Twice a yearNext edition: January 1, 2027· Claude · multi-AI consensus in a future edition· Published method· Order never changed by a human

Key metrics for this segment: lead program, total raised. Figures as published by each company or the press, dated, not recalculated. The AIs weigh them alongside funding history and comparables.

Not in this segment. AI drug discovery, in-vitro diagnostics and imaging & medical AI each have their own segment; manufacturing providers (CDMOs) and research tools are not ranked here. A company appears in one segment only. Method

The segment at a glance

13companies ranked

6companies on the radar

2countries in the ranking

6listed benchmarks

Sources: STAT, Fierce Biotech, BioPharma Dive, BioSpace, BusinessWire, PR Newswire, Labiotech, Drug Discovery Trends, Forge Global, Multiples.vc, Wikipedia, company announcements. Intention counters will be shown above a threshold of amount and number of Backers.

Rankings by region

Filter the ranking and the Radar. Ranks stay worldwide.

Global ranking · Gene & cell therapies

Top 13 Radar Challengers

First edition: no movements yet.

World · 13 ranked companies

#	Company	Last round · Key metrics	Estimated valuation (AI, order of magnitude)	Confidence	Invest
1	Altos LabsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series C · USD 1.5B reported (Forge data) · Feb 2024Cellular rejuvenation (reprogramming), preclinical (2026) · $3B at launch (2022)	Last known equity round: Series C · USD 1.5B reported (Forge data) · Feb 2024 (not confirmed here) Published valuation: USD 6.3B (Forge data) (Feb 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
2	Orca BioUnited States · North AmericaSources: 1 · 2 · 3 · 4Is this your company? Report an error	Series F · USD 250M aggregate (Series E and F) · Dec 2025Tregzi (Orca-T) FDA-approved for allogeneic transplant (Jul 2026) · $550M cumulative (2026)	Last known equity round: Series F · USD 250M aggregate (Series E and F) · Dec 2025 (led by Lightspeed Venture Partners) Published valuation: USD 2.4B (Forge data) (Jan 2026) Confidence index: HighMethod	Solid sources	Declare an intent
3	Kriya TherapeuticsUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series D · USD 320M · Sep 2025Two clinical programs (geographic atrophy, trigeminal neuralgia) · $1.2B+ since 2019 · 2025	Last known equity round: Series D · USD 320M · Sep 2025 (led by Patient Square Capital and Premji Invest) Published valuation: USD 1.67B (Forge data) (Sep 2025) Confidence index: HighMethod	Solid sources	Declare an intent
4	ArsenalBioUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series C · USD 325M · Sep 2024Programmable CAR-T for solid tumors, early clinical · Total raised: n/d · 2024	Last known equity round: Series C · USD 325M · Sep 2024 (ARCH Venture Partners, Regeneron Ventures, NVIDIA Ventures, T. Rowe Price, Bristol Myers Squibb, SoftBank Vision Fund 2) Published valuation: USD 1.66B (Forge data) (Sep 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
5	Mammoth BiosciencesUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series D-3 extension · USD 15M · Dec 2025Lead program: n/d · $379M · Dec 2025	Last known equity round: Series D-3 extension · USD 15M · Dec 2025 (not confirmed here) Published valuation: USD 1.35B (Forge data) (Apr 2024) Confidence index: MediumMethod	Partial sources	Declare an intent
6	Oricell TherapeuticsChina · Asia-PacificSources: 1 · 2Is this your company? Report an error	Pre-IPO round · USD 110M · Apr 2026Ori-C101 (GPC3 CAR-T, liver cancer) completed Phase 1 · ~$350M+ since 2015 · 2026	Last known equity round: Pre-IPO round · USD 110M · Apr 2026 (co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
7	Tessera TherapeuticsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series D · USD 150–200M (sources differ) · Dec 2025Lead program: n/d · $732M across 5 rounds · Dec 2025	Last known equity round: Series D · USD 150–200M (sources differ) · Dec 2025 (incl. Regeneron (strategic)) Published valuation: USD 668M (Forge data) (Dec 2025) Confidence index: MediumMethod	Partial sources	Declare an intent
8	Strand TherapeuticsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series B · USD 153M · Aug 2025STX-005 (mRNA in vivo CAR-T) (2026) · $250M+ (2025)	Last known equity round: Series B · USD 153M · Aug 2025 (incl. Eli Lilly, Amgen Ventures, Regeneron) Published valuation: USD 567M (Forge data) (Aug 2025) Confidence index: HighMethod	Solid sources	Declare an intent
9	Create MedicinesUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series B · USD 122M · May 2026MT-304 (HER2+ solid tumors) Phase 1/2; 50+ patients dosed (May 2026) · $245M cumulative (2026)	Last known equity round: Series B · USD 122M · May 2026 (led by ARCH Venture Partners, Newpath Partners, Hatteras Venture Partners) No confirmed published valuation Confidence index: LowMethod	Weak sources	Declare an intent
10	Umoja BiopharmaUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series C · USD 100M · Jan 2025UB-VV111 (in vivo CD19 CAR-T, partnered with AbbVie) (2026) · $374M (2025)	Last known equity round: Series C · USD 100M · Jan 2025 (incl. Alexandria Venture Investments, ARK Invest, Cormorant, SoftBank) Published valuation: USD 422M (Forge data) (Jan 2025) Confidence index: HighMethod	Solid sources	Declare an intent
11	Ray TherapeuticsUnited States · North AmericaSources: 1 · 2Is this your company? Report an error	Series B · USD 125M · Apr 2026Optogenetic gene therapy for vision restoration, clinical · $231M cumulative · 2026	Last known equity round: Series B · USD 125M · Apr 2026 (4BIO Capital, Adage Capital, Deerfield, Franklin Templeton and others) Published valuation: USD 384M (Forge data) (Apr 2026) Confidence index: HighMethod	Solid sources	Declare an intent
12	Tune TherapeuticsUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series B · USD 175M · Jan 2025Epigenome editing for chronic hepatitis B (clinical) · $223M · 2025	Last known equity round: Series B · USD 175M · Jan 2025 (incl. New Enterprise Associates, Hevolution Foundation, Regeneron) Published valuation: USD 356M (Forge data) (Jan 2025) Confidence index: HighMethod	Solid sources	Declare an intent
13	Arbor BiotechnologiesUnited States · North AmericaSources: 1 · 2 · 3Is this your company? Report an error	Series C-2 · USD 26M · Oct 2025ABO-101 gene editing for primary hyperoxaluria type 1, clinical · $332M · 2025	Last known equity round: Series C-2 · USD 26M · Oct 2025 (not confirmed here) Published valuation: USD 282M (Forge data) (Oct 2025) Confidence index: HighMethod	Solid sources	Declare an intent

Ranking in descending order of AI-estimated valuation, based on public information, following a published method, with no human intervention on the order. Valuation ranges are indicative editorial estimates: neither a financial valuation, nor an offer, nor investment advice. Only the market sets a company’s value, through a funding round or a sale. Edition 0: produced by Claude (Anthropic); a consensus of several AI models will apply in a future edition. Eligibility: at least $1M raised including one equity round, non-listed company, main activity in this segment (gene therapy, gene editing and cell therapy development). Country shown is the country of main operations. Request a correction

Get every new edition

New entries, exits and movements, twice a year.

One e-mail per edition. One-click unsubscribe. No data passed on to third parties.

How to read this ranking

Rank

Companies are ranked by AI-estimated valuation, highest first. The market sets the value; our AI estimates it.

Range

An order of magnitude, never a figure.

Hundreds of k$
Millions $
Tens of M$
Hundreds of M$
Unicorn
Decacorn

Confidence

High: recent published valuation or round (under 24 months).
Medium: older data.
Low: single or unconfirmed source.

Full method →

Invest in gene & cell therapies, together

Uback aggregates investment intentions from business angels, family offices, corporates and sector specialists worldwide. Every ranked company already has professional investors on its cap table, who have negotiated a shareholders’ agreement: you don’t start from a blank page.

Strength in numbers

Alone, a small ticket opens no doors. Together, Backers carry weight.

Declare an intention

On a company or a sector, with a ticket range. Paid, to show you are serious; transferable as long as it has not been converted.

Critical mass is reached

When the number of Backers and the total of their intentions cross a threshold, the licensed partner contacts the company and presents this demand.

The licensed partner structures

If the company’s expectations and the Backers’ converge, the partner builds a transaction and presents it directly to the Backers concerned.

Closing

Capital raise or sale of existing shares: small tickets are pooled in a common vehicle set up by the licensed partner. Each Backer decides whether to take part.

Uback does not advise, does not negotiate, collects nothing. Each transaction is run by the licensed partner of the company’s country, under the law that governs its shares.

Get notified when intentions open What happens after my declaration? Intention declarations open once the licensed partner signs · price per ticket band · valid 12 months · transferable credit

Challengers

A registered company raising funds that is not in the ranking will be able, for a fee, to appear in a separate list labelled “Challengers”, for a set period, with a memo available to verified Backers. The listing has no effect on the ranking. Not open yet.

Sponsored space · no Challenger listed yet

Radar · known eligible companies, not ranked

Sorted by date of last round, with no judgement and no AI call.

SonoThera · United States · North AmericaJun 2026 · USD 125M
Beacon Therapeutics · United Kingdom · EuropeJan 2026 · USD 75M
Vyriad · United States · North AmericaDec 2025 · USD 25M
ReCode Therapeutics · United States · North AmericaSep 2025 · USD 29M
nChroma Bio · United States · North AmericaDec 2024 · USD 75M
CPTx · Germany · Europe2024 · USD 29M

Listed benchmarks

Not ranked: no intention is possible on a listed company.

CRISPR Therapeutics · SwitzerlandNASDAQ · CRSP
Legend Biotech · United StatesNASDAQ · LEGN
Intellia Therapeutics · United StatesNASDAQ · NTLA
Beam Therapeutics · United StatesNASDAQ · BEAM
Prime Medicine · United StatesNASDAQ · PRME
Scribe Therapeutics · United StatesNASDAQ · SCTX

Sources and method for this segment

Calendar. Global segment rankings are published twice a year. Next edition: January 1, 2027.

Eligibility. At least $1M raised including one equity round, non-listed company, main activity in this segment (gene therapy, gene editing and cell therapy development). A company appears in one segment only.

Sources. STAT, Fierce Biotech, BioPharma Dive, BioSpace, BusinessWire, PR Newswire, Labiotech, Drug Discovery Trends, Forge Global, Multiples.vc, Wikipedia, company announcements.

Method and rules, common to all rankings →